Evotec: HC Wainwright & Co. Maintains Buy Rating, PT Down to $7
ByAinvest
Thursday, Aug 14, 2025 7:17 am ET1min read
EVO--
Analysts had expected a loss of 13 cents per share, with estimates ranging from -18 cents to -8 cents per share. The average earnings estimate for the quarter increased by about 3.7% in the last three months, with no revisions in the last 30 days. The current average analyst rating is "hold," with 2 "strong buy" or "buy" recommendations, no "hold" recommendations, and 1 "sell" or "strong sell" recommendation. The consensus recommendation for the biotechnology & medical research peer group is "buy" [1].
HC Wainwright & Co. maintained its "buy" rating on Evotec SE, but lowered its price target to $7.00 from $12.00, reflecting the company's recent earnings performance and guidance for the full year. The new price target is about 45.6% above the last closing price of $3.81 [1].
Evotec's first-half 2025 results were in line with expectations, with adjusted EBITDA of -€1.9 million, compared to -€0.5 million in the same period last year. The company expects full-year 2025 group revenues to range between €760 million and €800 million, with R&D expenditures ranging from €40 million to €50 million. Adjusted group EBITDA is expected to reach between €30 million and €50 million [2].
Evotec's shares have been volatile, with a 9.3% drop in the second quarter and an 8.4% decline year-to-date. The company's recent earnings performance and guidance may impact investor sentiment, but the "buy" rating from HC Wainwright & Co. suggests that the market still sees potential in Evotec's long-term prospects. Investors should closely monitor the company's progress and earnings releases to make informed decisions.
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U50DX:0-evotec-se-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] https://seekingalpha.com/news/4484553-evotec-se-reports-1h-results
Evotec: HC Wainwright & Co. Maintains Buy Rating, PT Down to $7
Evotec SE (EVO) reported its first-half 2025 results, with the company posting a quarterly adjusted loss of 12 cents per share, up from a loss of 27 cents per share in the same period last year [1]. Revenue decreased by 6% to €171.24 million compared to the prior year, falling short of analyst expectations of €205.14 million. The company's quarterly loss amounted to €43.48 million, while shares experienced a 9.3% drop during the quarter and an 8.4% decline year-to-date [1].Analysts had expected a loss of 13 cents per share, with estimates ranging from -18 cents to -8 cents per share. The average earnings estimate for the quarter increased by about 3.7% in the last three months, with no revisions in the last 30 days. The current average analyst rating is "hold," with 2 "strong buy" or "buy" recommendations, no "hold" recommendations, and 1 "sell" or "strong sell" recommendation. The consensus recommendation for the biotechnology & medical research peer group is "buy" [1].
HC Wainwright & Co. maintained its "buy" rating on Evotec SE, but lowered its price target to $7.00 from $12.00, reflecting the company's recent earnings performance and guidance for the full year. The new price target is about 45.6% above the last closing price of $3.81 [1].
Evotec's first-half 2025 results were in line with expectations, with adjusted EBITDA of -€1.9 million, compared to -€0.5 million in the same period last year. The company expects full-year 2025 group revenues to range between €760 million and €800 million, with R&D expenditures ranging from €40 million to €50 million. Adjusted group EBITDA is expected to reach between €30 million and €50 million [2].
Evotec's shares have been volatile, with a 9.3% drop in the second quarter and an 8.4% decline year-to-date. The company's recent earnings performance and guidance may impact investor sentiment, but the "buy" rating from HC Wainwright & Co. suggests that the market still sees potential in Evotec's long-term prospects. Investors should closely monitor the company's progress and earnings releases to make informed decisions.
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U50DX:0-evotec-se-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] https://seekingalpha.com/news/4484553-evotec-se-reports-1h-results
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet